Acceptability of Extended-Release Naltrexone as a Conduit to Care for HIV+ Criminal Justice Populations: Preliminary results of 2 double blind placebo controlled randomized trials

Sandra A. Springer, MD, Angela Di Paola, MS, & Frederick L. Altice, MD



Sandra A. Springer, MD Associate Professor of Medicine Section of Infectious Disease Yale School of Medicine





### Background

- HIV prevalence is 3x greater in CJS persons vs non-CJS <sup>11,12</sup>
- After release HIV+ prisoners do not adhere to ART and have ∱VL
  ♦CD4 within 3 months post-release<sup>1,2</sup>
- 50-60% of U.S. CJS have alcohol and drug use disorders (compared to 6 and 3% in the community); <sup>3,4</sup> and the majority relapse after release<sup>5</sup> which is associated with increased morbidity and mortality <sup>5,6</sup>
- Effective MAT for opioid & alcohol improves relapse prevention in the community, but is not routinely offered in CJS settings or at time of release <sup>7,8,9</sup>
- XR-NTX, a once monthly injectable opioid antagonist that is FDAapproved for alcohol and opioid dependence might assist in maintaining HIV VL suppression through prevention of relapse after release.<sup>9</sup>
- <u>The question is will XR-NTX be accepted by HIV+ CJ involved</u> persons?
- 1. Springer CID 2004
- 2. Baillargeon , JAMA 2010
- 3. Karberg, 2005
- 4. Peters, 1998

- 5. Springer CID 2011
- 6. Binswanger NEJM 2007
- 7. Oser DAD 2009
- 8. Chandler JAMA 2009
- 9. Springer PLoS ONE 2012

 Maruschak LM. *Bur* Justice Stat Bull. 2009.
 Spaulding. *PLoS One*.
 2009;4:e7558 2 Double Blind Placebo Controlled Randomized Trials of XR-NTX among HIV+ CJ-involved Persons R01-AA 018944 NIAAA (Inspire) & R01-DA 030762 NIDA (New Hope)





## **Injection Acceptability**

	COMBINED	INSPIRE	NEW HOPE		
Received Initial Injection	145 of 167 ( <b>86.8%)</b>	83 of 88 ( <b>94.3%</b> )	62 of 79 ( <b>78.5%</b> )		
Reasons did not receive injection					
Opioid dependent	3	0	3		
Positive for opioids	1	0	1		
Clinical need for opioids	4	2	2		
Inpatient Drug Treatment	4	2	2		
Moved out of area	1	0	1		
Quit study	1	0	1		
Refused injection	1	1	0		
Temporarily Lost	5	0	5		
Lost to follow-up	2	0	2		
Received Second Injection	86 of 145 ( <b>59.3%</b> )	48 of 83 ( <b>57.8%</b> )*	38 of 62 ( <b>61.3%</b> )		
Reasons did not receive injection					
Opioid dependent	3	0	3		
Clinical need for opioids	1	1	0		
Inpatient Hospital	1	0	1		
Inpatient Drug Treatment	5	2	3		
No recent labs on file	1	1	0		
Incarcerated	12	10	2		
Moved out of area	1	1	0		
Quit study	1	0	1		
Disenrolled, dementia	1	1	0		
Refused injection	3	3	0		
Temporarily Lost	22	14	8		
Lost to follow-up	7	1	6		
* plus 1 that did not receive the initial injection due to inpatient drug treatment					

\* plus 1 that did not receive the initial injection due to inpatient drug treatment

### **Demographic Information**

Baseline Characteristic	Total Group N=141	Returned for 2nd Injection N=83	Did NOT Return for 2nd Injection N = 58	
Study				
Inspire	57%	57%	43%	
New Hope	43%	62%	38%	
Gender				
Male	77%	60%	40%	
Mean age	44.7 (± 8.17)	45.1 (± 7.47)	44.3 (± 9.12)	
Race				
White non Hispanic	11%	56%	44%	
Black non Hispanic	48%	60%	40%	
Hispanic	41%	59%	41%	
Mean Months Incarcerated (N=138)	11.8 (± 22.80)	14.5 (± 28.38)	7.9 (± 9.10)	
Housing pre incarceration			· · · /	
Homeless	35%	56%	44%	
AUDIT Hazardous Drinking (N=138)	70%	54%	46%	
without hzd drinking	30%	73%	27%	
Prescribed ART at baseline	<b>78%</b>	64%	36%	
Experienced Serious Depression 30 days prior inc	56%	65%	35%	
Cocaine Postive Urine Tox. at Day of Release	15%	39%	61%	
Mini International Psychiatric Interview				
Current Major Depression (N=136)	35%	62%	38%	
Alcohol Use Disorder (N=135)	61%	55%	45%	
Narcotic Use Disorder (N=126)	50%	60%	40%	
Marijuana Use Disorder (n=117)	20%	65%	35%	
Cocaine Use Disorder (N=126)	71%	57%	43%	
Any Substance Use Disorder (N=135)	80%	58%	42%	
Any Alcohol AND SUD (N=134)	48%	41%	39%	
without comorbid Alcohol and SUD	<b>52%</b>	<b>67%</b>	33%	

Significant in Bivariate Regression p<0.10

# **Multiple Regression Model**

Baseline Characteristic	p value	Odds Ratio	95% Confidence Interval
AUDIT Hazardous Drinking*	0.159	0.448	0.146-1.371
Prescribed ART at baseline	0.975	0.981	0.293-3.278
Experienced Serious Depression 30 days prior incarceration	0.415	1.443	0.598-3.483
Cocaine Pos. Urine Toxicology on Day of Release	0.005	0.207	0.068-0.623
Any Alcohol AND SUD (N=134)	0.463	0.698	0.267-1.822

Goodness of Fit =.156

## Conclusions

- XR-NTX is highly acceptable among HIV+ CJS populations with opioid and alcohol use disorders and high levels of comorbid psychiatric illness
- Cocaine use disorders are associated with possible poorer treatment retention and interventions for cocaine treatment are urgently needed
- XR-NTX may be a feasible conduit to care for HIV+ opioid and alcohol use disorders among CJinvolved persons as they transition to the community

#### Acknowledgements

- NIAAA: R01-AA018944 (Springer, PI)
- NIDA:
  - R01:DA 030762 (Springer, PI)
  - K02: DA032322 (Springer, PI)
- Alkermes Inc.: Providing in-kind XR-NTX and placebo through Investigator-initiated applications
- The Participants!
- All Yale Clinical and Community Research Staff
- Angela Di Paola, MS (Project Coordinator)
- Connecticut Department of Correction (CTDOC):
- Springfield- Hampden County Correctional System and Bay State Medical Center: Tom Lincoln,MD and Dan Skiest ,MD and Maureen Desabrais